Navigation Links
Pharmexa A/S (DK) - Pharmexa presents data from influenza program

Summary: Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presents selected data from its influenza vaccine program today at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The data show that a "universal" vaccine designed to induce cell-mediated immune responses can protect transgenic mice against lethal experimental influenza virus challenge.

HORSOLM, Denmark, June 21, 2007-Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presented selected data from its influenza vaccine program today at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The company's "universal" vaccine strategy combines the use of multiple technologies developed over the past decade. Specifically, the experimental vaccine protected HLA transgenic mice, which are partially "humanized" against a lethal influenza virus infection.

The vaccine is designed to induce T-cell responses to highly-conserved influenza epitopes that were identified using the proprietary Epitope Identification System (EIS®). Pharmexa-Epimmune's approach is unique to the field where most vaccines are designed with the explicit goal of inducing antibody responses. The goal is to design and test a vaccine that will be protective as a "universal" influenza virus vaccine against both seasonal and pandemic viral strains.

Mark Newman, Ph.D., SVP, Global R&D Laboratories, noted: "These data are very promising and important to us for two reasons. First, we were able to demonstrate protection of the HLA transgenic mice from lethal influenza virus challenge using a vaccine designed to induce only T-cell responses. Second, we were able to demonstrate that the immune system of humans had recognized the selected vaccine epitopes as the result of past exposures to influenza virus and that the HLA transgenic mice responded in a similar manner."

Hørsholm, June 21, 2007

Jakob Schmidt Chief Executive Officer

Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525 Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558

Note to editors: Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.


'"/>




Related medicine technology :

1. Pharmexa A/S (DK) - Long lasting immune response and survival to RAS vaccine
2. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
3. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
4. Data supporting three Antisoma programmes presented at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has ... to their offering. ... The global chromatography market to grow at ... Chromatography Market 2016-2020, has been prepared based on an in-depth market analysis ... its growth prospects over the coming years. The report also includes a ...
(Date:12/8/2016)... 2016  Economic growth in the United States will ... management executives in their December 2016 Semiannual Economic Forecast. ... that began in mid-2009, as indicated in the monthly ... . The manufacturing sector is optimistic about growth in ... industries, and the non-manufacturing sector indicates that 14 of ...
(Date:12/8/2016)... 8, 2016 Noom, Inc., the leader in ... enterprise customers only when their members achieve real health ... wellness sector, which typically charges for arbitrary enrollment, participation ... The ... technology with the empathy of live human coaches to ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is in flux. The ... for the mass media launching of story movements to highlight what's most unfair ... unfortunate experiences; such a movement can generate the network power to improve healthcare ...
(Date:12/8/2016)... OH (PRWEB) , ... December 08, 2016 , ... ... insurance and financial planning services from offices headquartered in Hamilton County, is embarking ... rescue LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected ...
(Date:12/8/2016)... ... 08, 2016 , ... Coppin Insurance Agency, an insurance and financial planning firm ... Cape Coral area, is embarking on a charity drive with the goal of providing ... Harry Chapin Food Bank of Southwest Florida works to provide fresh and nutritious food ...
(Date:12/8/2016)... KS (PRWEB) , ... December 08, 2016 , ... ... financial consultation services to families and business owners in and around central Kansas, ... provide assistance to at-risk youth in the region. , Headquartered in Wichita, Youth ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... of the most comprehensive mental health systems reform legislation in more than fifty ... President, and the commitment of our elected officials to improving mental health services ...
Breaking Medicine News(10 mins):